International Journal of Medical Investigation
Tue, Dec 31, 2024
Volume 4, Issue 2 (June 2015)
Int J Med Invest 2015, 4(2): 245-248 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
ziabakhsh Tabary S, Yousefnejad K, Ziaee T, Fazli M. Assessment the clinical and paraclinical effects of enhanced external counter pulsation therapy in patients with coronary artery disease. Int J Med Invest 2015; 4 (2) :245-248
URL: http://intjmi.com/article-1-134-en.html
URL: http://intjmi.com/article-1-134-en.html
General Practitioner in Imam Khomeini Hospital of Esfarayen, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran
Abstract: (11193 Views)
Background: the aim of this study was assessment the clinical and paraclinical effects of enhanced external counter pulsation (EECP) therapy in patients with coronary artery disease. Patients and Methods: We performed a retrospective analysis of data related to all patients who received EECP treatment at Shafa hospitals in Sari, Iran from 21 March 2013 to 21 March 2015. All patient’s data included demographic data, history of underlying disease, clinical sign and symptom, laboratory data (hemoglobin, triglyceride (TG), cholesterol, Low-density lipoprotein (LDL), High-density lipoprotein (HDL)) and left ventricular ejection fraction (LVEF) in before and after treatment by EECP were collected. Results: the data of 48 patients (include 25 men) with mean age of 62.20±10.15 years were collected. The mean of TG, Cholesterol, LDL and HDL were not significantly change after EECP therapy. However, the mean of hemoglobin (10.47±0.81mg/dl vs. 10.20±1.03mg/dl, P=0.019) and LVEF (40.10±5.40% vs. 36.04±5.64%, P<0.0001) were significantly increased after EECP therapy. Also, the mean of systolic (112.81±6.75mmHg vs. 124.27±9.56mmHg, P<0.0001) and diastolic (71.35±5.90mmHg vs. 75.52±5.38mmHg, P<0.0001) blood pressure were significantly decrease after treatment with EECP. Clinical improvement of chest pain, muscle weakness, dyspnea and daily activity were observed in 14 patients (29.2%), 11 patients (22.9%), 24 patients (50%) and 28 patients (58.3%), respectively. Finally 31 patients (64.6%) were satisfy form this treatment. The complication included low back pain in 6 patients (12.5%) and paresthesia in 4 patients (8.3%). Conclusion: In conclusion, the results of our study show EECP therapy is a safe treatment and can reduced systolic and diastolic blood pressure, increase hemoglobin level and LVEF and improve clinical condition of CAD patients.
Keywords: coronary artery disease, enhanced external counter pulsation, left ventricular ejection fraction, clinical parameters, paraclinical parameters
References
1. 1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine. 2006;3(11):e442.
2. Steg PG, Bhatt DL, Wilson PW, D’Agostino R, Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. Jama. 2007;297(11):1197-206.
3. Ruparelia N, Kharbanda RK. Role of coronary physiology in the contemporary management of coronary artery disease. World Journal of Clinical Cases: WJCC. 2015;3(2):148.
4. Pettersson T, Bondesson S, Cojocaru D, Ohlsson O, Wackenfors A, Edvinsson L. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC cardiovascular Disorders. 2006;6(1):28.
5. Esmaeilzadeh M, Khaledifar A, Maleki M, Sadeghpour A, Samiei N, Moladoust H, et al. Evaluation of left ventricular systolic and diastolic regional function after enhanced external counter pulsation therapy using strain rate imaging. European Journal of Echocardiography. 2009;10(1):120-6.
6. Soran O, Kennard ED, Kfoury AG, Kelsey SF, Investigators I. Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry). The American journal of cardiology. 2006;97(1):17-20.
7. Yavari M, Montazeri H. Effects of enhanced external counterpulsation on anginal symptoms and improvements in objective measures of myocardial ischaemia: cardiovascular topic. Cardiovascular journal of Africa. 2007;18(3):154-6.
8. Soran O. A new treatment modality in heart failure: enhanced external counterpulsation (EECP). Cardiology in review. 2004;12(1):15-20.
9. Beck DT, Martin JS, Casey DP, Avery JC, Sardina PD, Braith RW. Enhanced external counterpulsation improves endothelial function and exercise capacity in patients with ischaemic left ventricular dysfunction. Clinical and Experimental Pharmacology and Physiology. 2014;41(9):628-36.
10. Braith RW, Conti CR, Nichols WW, Choi CY, Khuddus MA, Beck DT, et al. Enhanced External Counterpulsation Improves Peripheral Artery Flow-Mediated Dilation in Patients With Chronic Angina A Randomized Sham-Controlled Study. Circulation. 2010;122(16):1612-20.
11. Dockery F, Rajkumar C, Bulpitt CJ, Hall RJ, Bagger JP. Enhanced external counterpulsation does not alter arterial stiffness in patients with angina. Clinical cardiology. 2004;27(12):689-92.
12. Eftekhari A, May O. The immediate hemodynamic effects of enhanced external counterpulsation on the left ventricular function. Scandinavian Cardiovascular Journal. 2012;46(2):81-6.
13. Juneau M, Johnstone M, Dempsey E, Waters DD. Exercise-induced myocardial ischemia in a cold environment. Effect of antianginal medications. Circulation. 1989;79(5):1015-20.
14. Jawad E, Arora R. Chronic stable angina pectoris. Disease-a-Month. 2008;54(9):671-89.
15. Kozdağ G, Ertaş G, Aygün F, Emre E, Kirbaş A, Ural D, et al. Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure. Anadolu Kardiyol Derg. 2012;12:214-21.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
